DelveInsight’s, “Scleroderma Pipeline Insight, 2023,” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Scleroderma pipeline landscape. It covers the Scleroderma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Scleroderma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Scleroderma Pipeline Report

• DelveInsight’s Scleroderma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Scleroderma treatment.
• The leading companies working in the Scleroderma Market include Biocad, Certa Therapeutics, Emerald Health Pharmaceuticals, Acceleron Pharma, Kyowa Kirin, Bayer, Boehringer Ingelheim, Maruho Co., Ltd., Mitsubishi Tanabe Pharma, Prometheus Biosciences, and others.
• Promising Scleroderma Pipeline Therapies in the various stages of development include GS-248, Divozilimab, MEDI-551, Dasatinib, Nintedanib, treprostinil diethanolamine, and others.
• February 2023: Biocad announced a study of Phase 3 Clinical Trials for Divozilimab. The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20.
• September 2023: Janssen Pharmaceutical K.K. announced a study of Phase 2 Clinical Trials for Guselkumab Dose 1 and Guselkumab Dose 2. The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

 

Request a sample and discover the recent advances in Scleroderma Treatment Drugs @ Scleroderma Infection Pipeline Report

 

The Scleroderma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Scleroderma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Scleroderma clinical trial landscape.

 

Scleroderma Overview

Scleroderma is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. The combining form “sclero” means “hard” in Greek, and the word “dermis” means skin. There are two primary types of scleroderma: localized and systemic (also called systemic sclerosis).

 

Find out more about Scleroderma Treatment Drugs @ Drugs for Scleroderma Treatment

 

Scleroderma Emerging Drugs Profile

• FT011: Certa Therapeutics
• EHP 101: Emerald Health Pharmaceuticals
• ACE-1334: Acceleron Pharma

 

Scleroderma Pipeline Therapeutics Assessment

There are approx. 45+ key companies which are developing the therapies for Scleroderma. The Scleroderma companies which have their Scleroderma drug candidates in the most advanced stage, i.e. phase III include, Certa Therapeutics.

 

Learn more about the emerging Scleroderma Pipeline Therapies @ Scleroderma Clinical Trials Assessment

 

Scope of the Scleroderma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Scleroderma Companies- Biocad, Certa Therapeutics, Emerald Health Pharmaceuticals, Acceleron Pharma, Kyowa Kirin, Bayer, Boehringer Ingelheim, Maruho Co., Ltd., Mitsubishi Tanabe Pharma, Prometheus Biosciences, and others.
• Scleroderma Pipeline Therapies- GS-248, Divozilimab, MEDI-551, Dasatinib, Nintedanib, treprostinil diethanolamine, and others

 

Dive deep into rich insights for new drugs for Scleroderma treatment, Visit @ Scleroderma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Scleroderma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Scleroderma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Divozilimab: Biocad
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. FT011: Certa Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ACE-1334: Acceleron Pharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Scleroderma Key Companies
21. Scleroderma Key Products
22. Scleroderma- Unmet Needs
23. Scleroderma- Market Drivers and Barriers
24. Scleroderma- Future Perspectives and Conclusion
25. Scleroderma Analyst Views
26. Scleroderma Key Companies
27. Appendix

 

For further information on the Scleroderma pipeline therapeutics, reach out to Scleroderma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking